AN2 Therapeutics, Inc. (ANTX) has released an update.
AN2 Therapeutics, Inc. has paused Phase 3 enrollment of its clinical trial for epetraborole in treatment-resistant MAC lung disease after preliminary analysis indicated the drug might be less effective than expected. This halt will allow for a thorough review of the data and guidance from the DSMB on potential adjustments to the study. While the Phase 2 trial has been completed with 80 patients, the Phase 3 had a swift enrollment nearing 100 participants. Despite the pause, current trial participants will continue their treatment as the company prepares to release Phase 2 results in the summer of 2024.
For further insights into ANTX stock, check out TipRanks’ Stock Analysis page.
